A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures

Patient Preference and Adherence

Volumn 4, Issue , 2010, Pages 147-156

  Bonafede, Machaon M K ^a   Kalsekar, Anupama ^b   Pawaskar, Manjiri ^b   Ruiz, Kimberly M ^c   Torres, Amelito M ^c   Kelly, Karen R ^b   Curkendall, Suellen M ^c  

^a Thomson Reuters Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c THOMSON REUTERS   (United Kingdom)

Author keywords

Basal insulin; Insulin mixtures; Insulin persistence

Indexed keywords

EID: 77954597447     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/ppa.s10467     Document Type: Article

References (16)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596-615.
2. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31 Suppl 1:S12-S54.
3. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.
4. Catalan VS, Couture JA, Lelorier J. Predictors of persistence of use with the novel antidiabetic agent acarbose. Arch Intern Med. 2001;161: 1106-1112.
5. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patients population with type 2 diabetes mellitus. Clin Ther. 2001;23:1311-1320.
6. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glizipide oral therapy for type 2 diabetes. South Med J. 2002;95:68-71.
7. Oliveria SA, Menditto LA, Ulcickas Yood M, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23(12):3105-3112.
8. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20(10):1512-1517.
9. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014-1029.
10. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
12. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449-457.
13. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26(1):231-238.
14. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employersponsored health insurance. Clin Ther. 2005;27:1064-1073.
15. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin. 2009;25(3):777-786.
16. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007; 29:1294-1305.